AEON
AMEX AEON Biopharma, Inc. Class A$0.2445 ↑ +0.0148 (+6.44%) Trading Up from the previous close of $0.2297
- YTD change
- -77.77%
- vs 20-day SMA
- -8.96%
- vs 200-day SMA
- -66.63%
Price ranges
Price & Performance
-0.66 (-74.16%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $1,236.2400
- AEON is down 78% since the beginning of the year
- AEON is down 79% over the past 12 months
- AEON is down 8% over the past 1 month
- 9% of all AEON investors are betting against AEON
- Number of investors short AEON has gone up 20% versus last month
AEON reads not so good: price sits below both the 20- and 200-day averages, short interest is rising month over month, the 12-month move is -80.4%.
- Previous minute
- +$0.0135
- Last hour
- -$0.0005
- Last 5 days
- -15.60%
- vs 8-day SMA
- -11.54%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
AEON Biopharma, Inc. is a biopharmaceutical company, which engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
